Antisense oligonucleotide modulation of raf gene expression
AssigneeIsis Pharmaceuticals, Inc.
InventorBrett Monia
Life of this patent
Estimating the term…
Abstract
Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating or preventing conditions, including hyperproliferative conditions, associated with raf expression.
Claims15
1-10. (canceled)
A method of preventing or treating an ocular condition in an animal, said condition involving aberrant angiogenesis, comprising administering to said animal an oligonucleotide of 8 to 50 nucleotides in length that is targeted to mRNA encoding c-raf (SEQ ID NO:64).
Dependencies are inferred from the claim text.